Scholarlink

<p>Mammary mucinous cystadenocarcinoma (MCA) is an exceedingly rare subtype of breast carcinoma with fewer than 50 cases reported worldwide and limited molecular characterization. We investigated three mammary MCA cases using integrated histopathological assessment, tumor mutation burden (TMB) analysis and targeted next‑generation sequencing of 275 cancer‑associated genes. All tumors demonstrated characteristic multiloculated cystic architecture with papillary proliferations and abundant extracellular mucin. TMB values were uniformly low, ranging from 1.461 to 4.129 mutations/Mb. Representative pivotal alterations included <i>TP53</i> (truncating and missense) and <i>RB1</i> (truncating) mutations in all three cases, activating <i>PIK3CA</i> mutations (p.Q546K, p.H419Y) and oncogenic <i>AKT1</i> mutations (p.E49K, p.E17K) in two cases, whereas KRAS and TERT alterations were each identified in one case. The expanded targeted sequencing results further revealed additional pathogenic and likely pathogenic variants within <i>TP53</i>, <i>PIK3CA</i> and <i>KRAS</i>, particularly in case #1. Of note, the case #1 <i>PIK3CA</i> p.Q546K alteration was concordantly identified in our prior study. Overall, recurrent <i>TP53</i> and <i>RB1</i> involvement, together with frequent PI3K-AKT pathway abnormalities and low TMB, supports a distinctive molecular profile for mammary MCA by comparison to conventional mucinous breast carcinoma. These findings may assist in differential diagnosis when interpreted in conjunction with histomorphology and immunophenotype.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Molecular characterization of mammary mucinous cystadenocarcinoma reveals recurrent TP53 and RB1 alterations with frequent PI3K–AKT pathway abnormalities

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月19日

查看全文
  • Wei-Yu Chen,
  • Wan-Ching Chen,
  • Puay Hoon Tan,
  • Yi-Ming Chen,
  • Han-Ni Chuang,
  • Yu-Ting Kang,
  • Tzu-Hung Hsiao,
  • I-Tien Chiang,
  • I-Chieh Chen,
  • Chih-Jung Chen

摘要

Mammary mucinous cystadenocarcinoma (MCA) is an exceedingly rare subtype of breast carcinoma with fewer than 50 cases reported worldwide and limited molecular characterization. We investigated three mammary MCA cases using integrated histopathological assessment, tumor mutation burden (TMB) analysis and targeted next‑generation sequencing of 275 cancer‑associated genes. All tumors demonstrated characteristic multiloculated cystic architecture with papillary proliferations and abundant extracellular mucin. TMB values were uniformly low, ranging from 1.461 to 4.129 mutations/Mb. Representative pivotal alterations included TP53 (truncating and missense) and RB1 (truncating) mutations in all three cases, activating PIK3CA mutations (p.Q546K, p.H419Y) and oncogenic AKT1 mutations (p.E49K, p.E17K) in two cases, whereas KRAS and TERT alterations were each identified in one case. The expanded targeted sequencing results further revealed additional pathogenic and likely pathogenic variants within TP53, PIK3CA and KRAS, particularly in case #1. Of note, the case #1 PIK3CA p.Q546K alteration was concordantly identified in our prior study. Overall, recurrent TP53 and RB1 involvement, together with frequent PI3K-AKT pathway abnormalities and low TMB, supports a distinctive molecular profile for mammary MCA by comparison to conventional mucinous breast carcinoma. These findings may assist in differential diagnosis when interpreted in conjunction with histomorphology and immunophenotype.